Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 171 to 180 of 2450 total matches.
Lemborexant (Dayvigo) for Insomnia
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020 (Issue 1601)
)
was the first.1
Table 1. Pharmacology
Class Orexin receptor antagonist
Formulation 5, 10 mg tablets
Route ...
The FDA has approved lemborexant (Dayvigo – Eisai),
an orexin receptor antagonist, for treatment of sleep-onset
and/or sleep-maintenance insomnia in adults. It
is the second orexin receptor antagonist to be approved
for this indication; suvorexant (Belsomra) was the first.
Emtricitabine/Tenofovir Alafenamide (Descovy) for HIV
The Medical Letter on Drugs and Therapeutics • Aug 01, 2016 (Issue 1500)
The Medical Letter®
on Drugs and Therapeutics
Volume 58 (Issue 1500) August 1, 2016
Published ...
The FDA has approved Descovy (Gilead), a fixed-dose
combination of the nucleoside/nucleotide reverse
transcriptase inhibitors (NRTIs) emtricitabine (FTC)
and tenofovir alafenamide (TAF) for use with other
antiretroviral agents for treatment of HIV-1 infection. A
combination of emtricitabine and tenofovir disoproxil
fumarate (FTC/TDF; Truvada) has been available
since 2004 for the same indication. Emtricitabine
and TAF are also available in combination with the
non-nucleoside reverse transcriptase inhibitor
(NNRTI) rilpivirine as Odefsey and with the integrase
strand transfer...
In Brief: A New Glucagon Injection (Gvoke) for Severe Hypoglycemia
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019 (Issue 1585)
for use in patients ≥4 years old.1
Children ...
The FDA has approved a new formulation of glucagon
(Gvoke – Xeris) for subcutaneous treatment of severe
hypoglycemia in patients ≥2 years old with diabetes.
Conscious patients with symptoms of hypoglycemia can
take oral glucose. Glucagon is usually administered by a
caregiver to an unresponsive patient. The new formulation is
available in a single-use prefilled syringe (Gvoke PFS) and is
expected to become available in a single-use auto-injector
(Gvoke HypoPen) in 2020. Unlike previously available
injectable glucagon products (Glucagon Emergency Kit,
and others), Gvoke does not...
In Brief: Semaglutide (Wegovy) for Weight Loss in Children
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
IN BRIEF
Semaglutide (Wegovy) for Weight Loss in Children
The injectable glucagon-like peptide-1 ...
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide (Wegovy), which was
approved by the FDA in 2021 for chronic weight
management in adults, has now been approved for
chronic weight management in children ≥12 years old
with an initial BMI in the ≥95th percentile for age and
sex.Semaglutide is also available as Ozempic and
Rybelsus for treatment of type 2 diabetes in adults.
Med Lett Drugs Ther. 2023 Feb 20;65(1670):31-2 doi:10.58347/tml.2023.1670d | Show Introduction Hide Introduction
Dostarlimab (Jemperli) for Endometrial Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
, estimated PFS at 24 months
was also significantly higher with dostarlimab than
with placebo (36.1% vs 18.1 ...
The FDA has granted regular approval to dostarlimabgxly
(Jemperli – GSK), an immune checkpoint
inhibitor, for treatment of adults with mismatch repair
deficient (dMMR) recurrent or advanced endometrial
cancer that has progressed on or following a prior
platinum-containing regimen in any setting and who
are not candidates for curative surgery or radiation.
Dostarlimab received accelerated approval in 2021
for treatment of adults with dMMR recurrent or
advanced endometrial cancer or nonendometrial
solid tumors that progressed on or following prior
treatment and who have no...
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e64-5 doi:10.58347/tml.2023.1673h | Show Introduction Hide Introduction
In Brief: New Indications for Harvoni
The Medical Letter on Drugs and Therapeutics • Jan 04, 2016 (Issue 1485)
approved by the FDA in 2014 for treatment of hepatitis
C virus (HCV) genotype 1 infection,1 has now ...
Harvoni, a once-daily fixed-dose combination of the direct-acting antiviral agents ledipasvir and sofosbuvir approved by the FDA in 2014 for treatment of hepatitis C virus (HCV) genotype 1 infection,1 has now been approved for use in patients infected with HCV genotype 4, 5, or 6, and in patients co-infected with HCV and HIV-1. A 12-week course of treatment with Harvoni plus ribavirin has also been approved as an alternative to 24 weeks of Harvoni alone for treatment-experienced, cirrhotic patients with HCV genotype 1 infection.HCV genotypes 4, 5, and 6 are responsible for <2% of HCV cases...
A Combination of Fluticasone and Salmeterol For Asthma
The Medical Letter on Drugs and Therapeutics • Apr 16, 2001 (Issue 1102)
TREATMENT OF CHRONIC ASTHMA
Adult Pediatric
Drug Formulation Dosage Dosage
1
Cost
2
Beta
2 ...
Fluticasone propionate, an inhaled corticosteroid, and salmeterol xinafoate, a long-acting beta2-adrenergic agonist, are now available together in a dry-powder inhaler for maintenance treatment of patients with asthma. The new combination is not recommended for treatment of acute bronchospasm or for treatment of children less than 12 years old.
Montelukast (Singulair) for Perennial Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Oct 24, 2005 (Issue 1220)
cysteinyl
leukotriene D
4
receptor antagonist originally marketed
for treatment of asthma.
1 ...
Montelukast (Singulair - Merck) is an oral cysteinyl leukotriene D4 receptor antagonist originally marketed for treatment of asthma. It was approved by the FDA in 2003 for treatment of seasonal allergic rhinitis and recently for use in perennial allergic rhinitis in adults and children ≥ 6 months old. Intranasal corticosteroids have generally been considered the most effective drugs available for prevention and treatment of allergic rhinitis.
Vibrant – An Oral Vibrating Capsule for Chronic Idiopathic Constipation
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
,
and a need for manual maneuvers to aid defecation.1
STANDARD TREATMENT — Dietary changes, fiber
supplements ...
The Vibrant orally administered vibrating capsule
(Vibrant Gastro), an FDA-cleared medical device, is
now available by prescription for treatment of adults
with chronic idiopathic constipation (CIC) who have
not experienced relief of their bowel symptoms
by using laxative therapies at the recommended
dosage for at least one month. It is the first drug-free
treatment to be authorized by the FDA for this
indication.
Med Lett Drugs Ther. 2023 May 1;65(1675):65-7 doi:10.58347/tml.2023.1675a | Show Introduction Hide Introduction
Cariprazine (Vraylar) for Adjunctive Treatment of Depression
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
depression,
and for acute treatment of manic or mixed episodes
associated with bipolar I disorder.1
Table ...
The FDA has approved the second-generation
antipsychotic drug cariprazine (Vraylar — Abbvie) for
adjunctive treatment of major depressive disorder
(MDD) in adults. Cariprazine was previously approved
for treatment of schizophrenia and bipolar depression,
and for acute treatment of manic or mixed episodes
associated with bipolar I disorder.
Med Lett Drugs Ther. 2023 May 29;65(1677):84-6 doi:10.58347/tml.2023.1677c | Show Introduction Hide Introduction